IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies. We believe our proprietary IgM antibody technology platform is particularly well suited for developing T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers. Our lead product candidate, Imvotamab, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, and it is currently in two Phase 2 clinical trials for the treatment of relapsed and/or refractory diffuse large B cell lymphoma and follicular lymphoma. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with relapsed and/or refractory solid and hematologic malignancies, and it is currently in a Phase 1 clinical trial. Also in our product pipeline is IGM-7354 and IGM-2644. IGM-7354 is an anti-PD-L1 IgM antibody that targets the delivery of interleukin-15 (IL-15) cytokines to the area of PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma.
External link for IGM Biosciences, Inc.
325 E Middlefield Rd
Mountain View, California 94043, US
IGM Biosciences, Inc. reposted this
Join our team! We are seeking a cross-functional collaborative Director, Supply Planning and Project Management with skills in clinical supply management, long-range planning, and tech transfer. hashtag #IGMS #clinicalsupply #GMProjectmanagement #biotechtransfer
As we mark #WorldLupusDay, IGM recognizes the millions of people worldwide impacted by #lupus, including their families and friends. We are inspired to advance our research in SLE, RA, myositis, and other autoimmune diseases. #MakeLupusVisible; #LupusAwarenessMonth; #IGMLupus
IGM Biosciences, Inc. reposted this
We are thrilled to introduce our 2024 Greater Philadelphia #StudentVisionariesOfTheYear Leadership Committee Co-Chair, Sean Ahern, PharmD, RPh! Sean is currently an Associate Director, Clinical Scientist at IGM Biosciences, Inc.. He earned his Doctor of Pharmacy from Philadelphia College of Pharmacy at Saint Joseph’s University. This will be Sean’s third year with Student Visionaries. He is excited to meet and work with the 2024 candidate class! We are grateful to Sean’s ongoing commitment to developing the future generation of changemakers and bringing us closer to a cure. Thank you, Sean! To get involved with Student Visionaries, check out our website 👉 https://lnkd.in/g_smrzxq #LLSVisionaries #LLSEPADE